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Abstract The costs associated with the care of Alzhei-
mer’s disease patients are very high, particularly those
associated with nursing home placement. The combination
of a cholinesterase inhibitor (ChEI) and memantine has
been shown to significantly delay admission to nursing
homes as compared to treatment with a ChEI alone. The
objective of this cost-effectiveness analysis was to evaluate
the economic impact of the concomitant use of memantine
and ChEI compared to ChEI alone. Markov modelling was
used in order to simulate transitions over time among three
discrete health states (non-institutionalised, institutiona-
lised and deceased). Transition probabilities were obtained
from observational studies and French national statistics,
utilities from a previous US survey and costs from French
national statistics. The analysis was conducted from soci-
etal and healthcare system perspectives. Mean time to
nursing home admission was 4.57 years for ChEIs alone
and 5.54 years for combination therapy, corresponding to
0.98 additional years, corresponding to a gain in quality
adjusted life years (QALYs) of 0.25. From a healthcare
system perspective, overall costs were €98,609 for ChEIs
alone and €90,268 for combination therapy, representing
cost savings of €8,341. From a societal perspective, overall
costs were €122,039 and €118,721, respectively, repre-
senting cost savings of €3,318. Deterministic and proba-
bilistic (Monte Carlo simulations) sensitivity analyses
indicated that combination therapy would be the dominant
strategy in most scenarios. In conclusion, combination
therapy with memantine and a ChEI is a cost-saving
alternative compared to ChEI alone as it is associated with
lower cost and increased QALYs from both a societal and a
healthcare perspective.
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Introduction
Alzheimer’s disease (AD) is an irreversible, degenerative
brain disease characterised by progressive cognitive dys-
function, associated with behavioural and neuropsychiatric
disturbances and functional disability. It is the most pre-
valent neurodegenerative disease and the most frequent
cause of dementia in elderly populations [1]. The preva-
lence of AD is growing because of the increased longevity
of the general populations [2]. It has been estimated that,
worldwide, around 35.6 million people have AD, and this
figure is expected to increase to 65.7 million by 2030 and
115.4 million by 2050 [3]. A long-term prospective lon-
gitudinal cohort study (PAQUID) of the ageing population
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estimated the prevalence of AD in France to be 4.3 %,
doubling with approximately every 5 extra years of age,
with an incidence of 1.17 per 100 person years [4]. The
total number of cases of AD in France in 2006 has been
estimated to be around 900,000 [5].
The costs associated with the care of AD patients are
very high, with an estimated per capita annual total cost in
the EU of €22,000 in 2008 [6]. This corresponds to a
potential total annual cost of €160 billion. In a multi-
national study of the economic burden of Alzheimer’s
disease in 2007 [7], the total cost of all-cause dementia in
France was €24 billion, of which informal care costs (€13.5
billion) and nursing home care (€9 billion) were the largest
contributors. In addition, patients with dementia account
for around one half of all nursing home residents in France
[8]. For this reason, delaying nursing home admission may
have an impact on the overall costs associated with the
disease [9]. The principal factors driving nursing home
admission are severity of cognitive impairment, depen-
dency in activities of daily living, and prominent behav-
ioural and psychological symptoms of dementia (BPSD)
[10, 11], and treatments ameliorating these functions may
be of interest in this respect.
Approved treatments for AD in Europe consist of cho-
linesterase inhibitors (ChEI) such as donepezil, rivastig-
mine and galantamine [12] for mild-to-moderate AD and
the NMDA receptor antagonist memantine [13, 14] for
moderate-to-severe AD. The evidence for the efficacy of
memantine in slowing the clinical progression of AD, in
improving cognition, memory, communication and the
ability to perform daily activities has been reviewed
recently [15]. The ability of memantine to decrease
symptomatic decline and to improve functioning in patients
with moderately severe-to-severe AD was originally dem-
onstrated in two pivotal phase III trials [16, 17] and has
subsequently been confirmed in other studies. A meta-
analysis of available data published in 2007 concluded that
memantine had clinically relevant efficacy in patients with
moderate-to-severe AD [18]. In addition, a beneficial effect
has also been demonstrated on BPSD [19]. It was subse-
quently shown that memantine, when given in combination
with a ChEI, provided added benefit over ChEIs alone [20].
There is also some evidence that early treatment initiation
may increase the chances of an adequate treatment
response to memantine [15].
Since the disease features influenced by memantine are
important predictors of nursing home admission, it is
possible that early treatment with this drug may delay
admission to nursing homes. Indeed, a randomised clinical
trial comparing memantine to placebo in patients with AD
living in the community has provided evidence for a delay
in time to nursing home admission and a reduction in
caregiver time in patients treated with memantine [21].
Subsequently, an observational study showed that the
combination of a ChEI and memantine significantly
delayed admission to nursing homes as compared to
treatment with a ChEI alone [9].
A cost-effectiveness study published in 2001 using the
Assessment of Health Economics in Alzheimer’s Disease
(AHEAD) model [22] suggested that the costs of early
treatment with a ChEI could be largely offset by a reduc-
tion in nursing home costs associated with delayed
admission [23]. A more recent pharmacoeconomic mod-
elling study performed in the context of the Canadian
healthcare system suggests that this may also be the case
for combination therapy with memantine and ChEI, which
is more cost-effective than treatment with ChEIs alone
because of reduced nursing home costs [24]. However,
before drawing a general conclusion from only one study, it
is important to ensure that the same health outcomes and
economic benefits associated with concomitant memantine
and ChEI use compared to ChEI alone with regard to time
to nursing home admission can be expected in the context
of other healthcare systems, where treatment costs, reim-
bursement rules and attitudes to nursing home care may
vary considerably. For this reason, we have conducted the
present analysis in the French healthcare context. The
research question addressed was whether use of combina-
tion therapy with memantine and ChEI would be cost-
effective at standard willingness-to-pay thresholds from
both societal and healthcare system perspectives.
Methods
A cost-effectiveness analysis was conducted to evaluate the
economic impact of the concomitant use of memantine and
ChEI compared to ChEI alone on the time to nursing home
admission. Markov modelling was used in order to simu-
late transitions over time between discrete health states,
each associated with different unit costs. The evaluation
was undertaken from a societal perspective and also from
the publicly funded healthcare system perspective. For this
cost-effectiveness analysis, treatment with ChEI mono-
therapy was considered the reference care paradigm. The
three ChEIs licensed and reimbursed for the treatment of
AD in France are donepezil, rivastigmine and galantamine.
This evaluation was conducted in compliance with the
French guidelines available at the time of the study (CES
guidelines for the Economic Evaluation of Health Tech-
nologies in France) [25].
Markov model
The Markov model considered three states. These were
non-institutionalised (not admitted to a nursing home),
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institutionalised (admitted to a nursing home) and deceased
(Fig. 1). The cohort simulated patients living in the com-
munity starting treatment for AD and who had not previ-
ously been admitted to a nursing home. The age and gender
distributions of the study population were derived from the
study by Lopez et al. [9], in which the ChEI monotherapy
group had an average age of 76 years old and in which
68.5 % of participants were women. All patients were thus
in the non-institutionalised state initially, from where they
could move to one of the other two states or remain in the
non-institutionalised state at the end of each cycle. It was
considered that once patients had entered a nursing home,
they would not leave it again. This assumption is supported
by a recent survey of nursing home residents in France, of
whom less than 1 % return home over a 3-month period
[26]. Each cycle corresponded to 1 year and the cohort was
simulated over 7 years. This time horizon was chosen since
it corresponds to that used in the clinical study of Lopez
et al. [9], which was used to generate the transition prob-
abilities for nursing home admissions. In addition, it
encompasses the median survival time of AD patients
observed in the PAQUID study and thus should be suffi-
cient to capture all relevant benefits of treatment. The
structure of the model was identical to that used in the
previous Canadian cost-effectiveness study [24].
Transition probabilities
The probabilities of transition from the non-institutionalised
state to the institutionalised state were estimated from data
in the Lopez study [9] (Table 1). These transition proba-
bilities differed between the ChEI alone and combination
therapy treatment groups, and varied with time across the
seven yearly cycles of the model. The transition probability
from the non-institutionalised state to death was estimated
from all-cause mortality data taken from French mortality
tables [27] and adjusted for specific AD-related mortality
and for the age and gender distribution of the sample (cal-
culations not shown, available from authors on request).
The transition probability between the institutionalised state
to death was assumed to be identical to that from the non-
institutionalised state to death considered to be independent
of treatment. Assuming a different (most likely higher)
mortality for institutionalised patients compared to non-
institutionalised ones would have led, because of the model
structure, to a spurious indirect impact of treatment on life
expectancy (through the impact of treatment on institu-
tionalisation). No impact of combination treatment on
mortality having been actually observed in the study by
Lopez et al. [9], it was therefore decided to use the same
death probabilities for institutionalised and non-institu-
tionalised patients in the model. The transition probabilities
used in the model are presented in Table 1.
Utility values
The utility values associated with the institutionalised and
non-institutionalised states were the same as those used in
an application of the AHEAD model to early treatment with
galantamine [23]. However, it should be noted that the
‘non-institutionalised’ and ‘institutionalised’ states used in
our model are not strictly identical to the ‘no full time care’
and ‘full time care’ states of the AHEAD model. The utility
values were originally derived from a large survey of
patients and carers conducted in the US in the 1990s [28], in
which utilities were estimated for different levels of disease
severity using the Health Utilities Index Mark II, a generic
preference index based on the standard gamble. We applied
the mean utility score for patients with mild and moderate
disease (0.60) to non-institutionalised patients and the mean
utility score for patients with severe, profound or terminal
disease (0.34) to institutionalised patients. These values
were used as weights to calculate QALYs.
Costs
The costs considered in the analysis included the costs of
medication (ChEI and ChEI plus memantine) and also the
costs associated with care provided either in the commu-
nity or in nursing homes. Medication costs were assigned
from unit costs reimbursed by the CNAMTS (French
national health insurance) [29]. The same unit costs were
applied to both nursing home and community care.
Regarding the cost of care in either the community or




Fig. 1 Structure of the Markov model
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report of the French Assembly on AD [30] and were
updated to 2010 levels after the application of the inflation
rate using OECD 2005–2010 consumer price inflation rate
(Table 2).
The costs considered in the analysis including costs of
medication (ChEI and ChEI plus memantine) as well as
costs associated with care either in the community or in a
nursing home are summarised in Table 3.
Benefit measures and valuation
The primary outcome measure for the evaluation was the
incremental cost-effectiveness ratio (ICER), expressed as
cost per quality-adjusted life years (QALY) gained. As
recommended by the CES [25], the estimated costs and
QALYs were discounted at a rate of 0, 3 and 5 %. The base
case analysis was discounted at 3 % and discount rates of 0
and 5 % were applied to estimated costs and QALYs in
supportive analyses. Half-cycle corrections were per-
formed where required.
Sensitivity analyses
Deterministic sensitivity and probabilistic analyses were
carried out to assess the robustness of the model.
For the deterministic approach, arbitrary variations
of ±20 % were applied to the cost and utility parameters
(Table 4) and of 50 to 200 % to the transition probabilities
(Tables 5, 6). As these variations do not have any impact
on transition probabilities equal to zero (probabilities of
institutionalisation years 6–7 for the ChEIs alone group and
years 1–2–3–6–7), probabilities were also smoothed in
order to explore the impact of these null probabilities fur-
ther. Smoothing of transition probabilities was performed
by considering the proportion of patients who were insti-
tutionalised at the end of the observation period (7 years),
and assuming a constant hazard (i.e. exponential survival
model) over the preceding years. For the deterministic
sensitivity analyses, two different willingness-to-pay
(WTP) thresholds were used, based on current NICE
guidelines [31] of £20,000/QALY (€23,065/QALY) for the
lower threshold and £30,000/QALY (€34,598/QALY) for
the upper threshold.
A probabilistic sensitivity analysis was also performed
on all the variables using the Monte Carlo method. A total
of 10,000 trials were run for the Monte Carlo simulation
according to the assigned probability distributions. A tri-
angular distribution was used for all cost and utility
parameters. A triangular distribution was also used for the
probability of institutionalisation over time. Upper and
lower bounds for the probability of institutionalisation
were taken from the best and worst case scenarios.
All deterministic and probabilistic sensitivity analyses
were conducted from both a publicly funded healthcare
system and a societal perspective. The former took into
account only direct medical costs and the latter all direct
and indirect costs.










One 0.0167 0 0.0300
Two 0.1031 0 0.0335
Three 0.0947 0 0.0375
Four 0.0808 0.0167 0.0421
Five 0.0891 0.0418 0.0475
Six 0 0 0.0539
Seven 0 0 0.0612
a Data were extracted from Fig. 3 of the Lopez et al. publication [9]
using Grafula 3 version 2.10 software
b French survival tables adjusted for death specifically related to AD
(calculations not shown, available from authors on request)
Table 2 Annual costs
Description 2005 value (€) 2010 value (€)
Costs of medication
Cholinesterase inhibitors – 855
Memantine – 1,158
Costs of community carea 17,104 18,757
Direct costs (excluding medication)
Medical visits 285 313
Hospitalisations 185 203
Nurses 3,326 3,647
Dependency assistance 5,088 5,580
Family contributions 768 842
Other financial aids 2,772 3,040
Indirect costs
Informal help 4,680 5,132
Costs of nursing home carea 26,301 28,843
Direct costs (excluding medication)
Medical visits 285 313
Hospitalisations 184 202
Care fee 6,560 7,194
Dependency fee 4,872 5,343
Accommodation fee 14,400 15,792
Cost categories correspond to those provided in the 2005 national
report of the French Assembly on AD [30]
a Original costs are 2005 and were updated to 2010 levels based
using OECD 2005–2010 consumer price inflation rate
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Data analysis and quality control
This economic evaluation was performed using Microsoft
Office Excel 2007. The probabilistic sensitivity analyses
were performed using Crystal Ball V11.1.2.3. To validate
the results, all the analysis components were independently
reviewed by two researchers (Catherine Beauchemin and
Jean Lachaine, Montreal Pharmacy University). Grafula 3
version 2.10 was used to extract the survival curve data.
Results
Cost effectiveness analysis
Over the 7-year time horizon, the mean time to nursing
home admission was 4.57 years for patients receiving
ChEIs alone and 5.54 years for those receiving combina-
tion therapy, corresponding to 0.98 additional years
(approximately 1 year) spent in the community for patients
receiving combination therapy. This translated into 3.11
QALYs for ChEIs alone and 3.37 QALYs for combination
therapy, representing a gain in QALYs of 0.25.
From a healthcare system perspective, overall costs
were €98,609 for ChEIs alone and €90,268 for combination
therapy, representing a cost saving of €8,341. From a
societal perspective, overall costs were €122,039 for ChEIs
alone and €118,721 for combination therapy, representing
a cost saving of €3,318. From both perspectives, combi-
nation therapy is thus a cost-saving and dominant strategy
compared to ChEI alone (Table 7). This analysis was
performed at a 3 % discount rate. When applying discount
rates of 0 and 5 %, combination therapy was consistently
dominant over ChEIs alone at both discount rates and from
both perspectives (data not shown).
Sensitivity analyses
The scenarios tested in the deterministic sensitivity anal-
yses are described in Tables 4, 5, 6. The results of these
analyses confirmed the results of the cost-effectiveness
analysis for the base case, with combination therapy
remaining the dominant alternative in most scenarios.
From a healthcare system perspective, combination
therapy remained dominant over ChEI alone in 17 out of 18
scenarios (Fig. 2). The one situation where combination
Table 3 Direct and indirect costs per patient in each transition state
Annual costs/patient (€) State
Non-institutionalised Institutionalised Death
ChEI ChEI ? MEM ChEI ChEI ? MEM ChEI ChEI ? MEM
Medications 855 2,013 855 2,013 0 0
Other direct costs 13,625 13,625 28,843 28,843 0 0
Indirect costs 5,132 5,132 0 0 0 0
Table 4 Scenarios used in the deterministic sensitivity analysis (costs and utility parameters)
Analysis Parameter Base value Variation (compared







Costs of community Direct costsa 13,625 80 10,900 2 Triangular
120 16,350 3 Triangular
Indirect costs 5,132 80 4,106 4 Triangular
120 6,159 5 Triangular
Cost of institution Direct costsa 28,843 80 23,074 6 Triangular
120 34,611 7 Triangular
Utilities Community 0.60 80 0.48 8 Triangular
120 0.72 9 Triangular
Institution 0.34 80 0.27 10 Triangular
120 0.41 11 Triangular
a No sensitivity analysis was conducted on treatment costs as there is no uncertainty related to this parameter
b Distributions used for the probabilistic analysis
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therapy was not dominant was when the worst case sce-
nario for the probability of institutionalisation was applied
(scenario 14). In this case, the ICER for combination
therapy was 13,342 €/QALY, which could nevertheless be
considered cost-effective at willingness to pay thresholds
of both €23,065 and €34,598.
From a societal perspective, combination therapy was
dominant over ChEI alone in 15 out of 18 scenarios. For
the other three scenarios, the combination therapy was
deemed cost-effective compared to ChEI alone at the
higher willingness-to-pay threshold of €34,598. Two of
these scenarios (scenario 6: ICER 9,146 €/QALY; scenario
12: ICER 9,529 €/QALY) remained cost-effective at the
lower willingness-to-pay threshold of €23,065, but the
combination was no longer deemed cost-effective for sce-
nario 14 (ICER: 33,082 €/QALY; Fig. 3).
A probabilistic sensitivity analysis was also performed
using Monte Carlo simulations. From a public healthcare
system perspective, combination therapy was a dominant
strategy in 99.5 % of the Monte Carlo simulations and was
cost-effective in 99.9 % of simulations with WTP thresh-
olds of both €23,065 and €34,598. From a societal per-
spective, combination therapy was a dominant strategy in
87.0 % of the Monte Carlo simulations and was cost-
effective in 99.7 % (lower WTP threshold) and 99.8 %
(upper WTP threshold) of simulations.
Discussion
This cost-effectiveness analysis evaluated the economic
consequences of two different treatment options for man-
agement of patients with AD living in the community,
taking into account the impact on nursing home admission
in the French setting. Compared to ChEIs alone, adding
memantine to treatment increased the number of QALYs
gained and decreased costs due to reduced time spent in



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6 Scenarios used in the deterministic sensitivity analysis
(transition probabilities–death)
Years Probabilities of death
Base-case scenario 50 % 200 %
1 0.0300 0.0150 0.0600
2 0.0335 0.0167 0.0670
3 0.0375 0.0187 0.0749
4 0.0421 0.0210 0.0842
5 0.0475 0.0238 0.0951
6 0.0539 0.0269 0.1078
7 0.0612 0.0306 0.1225
Scenario 17 18
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memantine and a ChEI is a cost-saving alternative com-
pared to ChEI alone, as it is associated with lower costs and
increased QALYs from both societal and healthcare
perspectives.
These results are consistent with those found in a pre-
vious application of the same model to the Canadian setting
[24] and with findings of a different model performed in a
US setting, in which decline in cognitive function was
simulated over 1 year, and the combination of memantine
with ChEIs was also found to be cost-effective with respect
to ChEIs alone [32]. In all these countries, the overall
management costs of Alzheimer’s disease can be signifi-
cantly reduced by combining memantine treatment with
acetylcholinesterase inhibitors, irrespective of the model
used, which supports the robustness of the findings
obtained. This is important, since it has previously been
reported that the Markov model used in the pharmaco-
economic evaluation from the 2007 NICE evaluation [33]
was unstable and very sensitive to small changes in input
parameters [34].
An important assumption made in our model was that
treatments would be used continuously over a lifetime.
However, this is unlikely to be the case, since treatment is
often discontinued in nursing homes as the disease pro-
gresses. The source data that we used for the impact of
treatment on institutionalisation was extracted from an
observational study of real-life conditions of treatment use
[9]. In this study, patients did not in fact receive memantine
for the whole 7-year study follow-up (mean treatment
duration: 19.2 months). As a consequence, the lifetime
treatment assumed in the model does not lead to an over-
estimation of effectiveness. On the other hand, the cost of
treatment is applied for as long as patients are alive and is
thus overestimated. The lifetime treatment assumption is
consequently a conservative one. We also assumed that
medication adherence would be complete in the commu-
nity setting, whereas observational studies have indicated
that adherence of patients with AD to antidementia drugs is
suboptimal [35]. Adherence was not documented in the
study that was the source of our data. However, again, if
Table 7 Incremental cost-effectiveness analysis (base case)
Survival
(years)








Costs (€) Costs (€)
ChEI alone 5.66 63 % 4.57 3.11 98,609 122,039
ChEI ? memantine 5.66 63 % 5.54 3.37 90,268 118,721
Incremental 0 0.98 0.25 -8,341 -3,318
ICER – – – – Dominant Dominant
























Incremental values (ChEI+ MEM) - ChEI
WTP 
thresholds
23,065 € 35,598 €
Favors ChEI+MEM
0 €
Fig. 2 Deterministic sensitivity
analysis (healthcare
perspective). * All scenarios
resulted in a positive
incremental effectiveness gain
for combination therapy
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adherence is overestimated, this would artifactually inflate
treatment costs, resulting in a conservative estimate of
cost-effectiveness.
Strengths of this model were that transition probabilities
for nursing home admissions were based on real-life data
for time to nursing home admission in the two treatment
strategies [9] rather than on simulations. These data come
from a prospective observational study that is more rele-
vant for cost-effectiveness analysis than data from experi-
mental settings such as randomised clinical trials.
Moreover, that costs of care were identified from a recent
and relevant official parliamentary report [30]. In addition,
the model was iterated over a 7-year time horizon, using
measured rather than extrapolated data to determine the
transition probabilities. This time horizon is consistent with
the expected survival of patients with AD [36]. Finally, an
extensive range of sensitivity analyses was performed with
regard to the different input parameters, in which combi-
nation therapy was consistently found to be cost-effective
over ChEIs alone, suggesting that the findings should be
considered to be robust.
This study also has several limitations. An important
limitation is that local data were not available for all the
input variables of the model. Whereas recent French data
exist for mortality and costs, there are no local long-term
epidemiological data available for time to admission to
nursing homes, and we were obliged to use data from a
study performed in the USA [9]. Given potential differ-
ences in the healthcare systems between France and the
USA, the relevance of these US data to the French context
is unknown. Similarly, there are no available French data
on utilities, and we again used data from a North American
study. However, even if there may be issues with trans-
posability, this was addressed in the sensitivity analyses,
which demonstrated that the findings were robust and were
not altered when utility values and nursing home placement
probabilities were modified. Other limitations reflect the
limitations of the observational study used as the source for
the data on institutionalisation. These have been discussed
in detail elsewhere [9] and include lack of randomisation
and the subsequent imbalance between the two groups with
respect to prognostic risk factors, temporal variation in
factors other than treatment that affect institutionalisation
and mortality, and a potential Hawthorne effect due to
better care provision in the context of the study.
In addition to providing cost savings, as demonstrated
by the present cost-effectiveness analysis, delaying
admission to nursing homes by providing combination
treatment with memantine and ChEI may also be beneficial
in terms of patient well-being. A survey of caregivers
indicated that admission of AD patients to nursing homes is
considered to be a major negative determinant of their
quality of life, with more than two-thirds of AD caregivers
rating delaying admission as an ‘extremely important’ or
‘very important’ way of maintaining quality of life [37].
Keeping the AD patient at home for as long as possible has
thus been identified as a goal for both patients and care-
givers [37, 38] and providing support to caregivers iden-
tified as a useful strategy to increase the time that AD
patients can remain at home [39]. Building such caregiver

























Incremental values (ChEI+ MEM) -ChEI
 €
23,065 € 34,598 €
WTP 
thresholds
Fig. 3 Deterministic sensitivity
analysis (societal perspective).
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support is one of the principal strategic axes of the Alz-
heimer Plan developed in 2008 by the French health
authorities to optimise the management of AD patients and
to improve the quality of life of both AD patients and their
caregivers [40]. In parallel to this, adequate antidementia
treatment, and in particular the combination of memantine
with ChEIs, could also contribute to allowing AD patients
to be managed longer in the community setting [9, 15, 21,
41] and thus help preserve their quality of life.
In conclusion, this economic evaluation indicates that,
from both healthcare system and societal perspectives,
combination therapy with memantine and a ChEI is a cost-
saving strategy in the management of AD patients com-
pared with ChEIs alone.
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